As part of its RPA strategy, Merck leveraged unattended bots from Automation Anywhere to automate and streamline the creation, management, and distribution of its regulatory processes.
“The initiative began in 2021. We started with the APAC region and then scaled up the solution to Latin America and the US regions. It took us two years to implement the solution. By the time the project ended in December 2022, we had covered 23 geographies and 43 processes, including trade compliance, cross-country logistics, and regulatory management.”
Dr. Radhika Mahadev, Head of Robotic Process Automation, Merck Life Science
By automating manual processes, Merck has saved crucial time, which can now be used for more meaningful tasks.
“Regulatory SMEs (subject-matter experts) from 23 geographies can now focus on higher-value operations by delegating monotonous chores to RPA. It enhanced the accuracy level and compliant by on-time submission of the regulatory documents. It helped us save 121K human hours, allowing us to allocate more time toward other valuable tasks.”
Dr. Radhika Mahadev
On the future of automation at the company, Mahadev says, “Merck is looking forward to the cognitive capabilities. Handling unstructured data and the decision-making process are the need of the hour. Improvements in cognitive capabilities might be beneficial in shifting the focus away from rule-based automation and toward unstructured data.”
